A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
US: FDA approval not reviewed here
The registry reports terminated. This is trial metadata, not an assessment of treatment benefit.
Phase 2 · Stopped early
Registry enrollment: 65 participants
Study ages: 18 Years to 55 Years
Results posted Nov 12, 2026
Read trial record and resultsChecked Nov 17, 2026